<- Go Home
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Market Cap
EUR 2.6B
Volume
70.1K
Cash and Equivalents
EUR 27.8M
EBITDA
EUR 256.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 326.5M
Profit Margin
32.94%
52 Week High
EUR 28.50
52 Week Low
EUR 12.62
Dividend
1.03%
Price / Book Value
2.79
Price / Earnings
18.35
Price / Tangible Book Value
2.88
Enterprise Value
EUR 2.9B
Enterprise Value / EBITDA
10.49
Operating Income
EUR 176.7M
Return on Equity
16.08%
Return on Assets
7.13
Cash and Short Term Investments
EUR 27.8M
Debt
EUR 301.8M
Equity
EUR 944.1M
Revenue
EUR 991.2M
Unlevered FCF
-EUR 21.6M
Sector
Life Sciences Tools and Services
Category
N/A